NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.

Cell Rep

Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA; Department of Biochemistry & Molecular Biology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA; Sorbonne Université, INSERM, CRSA, 75012 Paris, France. Electronic address: azeddin

Published: November 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A long-standing question in the pancreatic ductal adenocarcinoma (PDAC) field has been whether alternative genetic alterations could substitute for oncogenic KRAS mutations in initiating malignancy. Here, we report that Neurofibromin1 (NF1) inactivation can bypass the requirement of mutant KRAS for PDAC pathogenesis. An in-depth analysis of PDAC databases reveals various genetic alterations in the NF1 locus, including nonsense mutations, which occur predominantly in tumors with wild-type KRAS. Genetic experiments demonstrate that NF1 ablation culminates in acinar-to-ductal metaplasia, an early step in PDAC. Furthermore, NF1 haploinsufficiency results in a dramatic acceleration of Kras-driven PDAC. Finally, we show an association between NF1 and p53 that is orchestrated by PML, and mosaic analysis with double markers demonstrates that concomitant inactivation of NF1 and Trp53 is sufficient to trigger full-blown PDAC. Together, these findings open up an exploratory framework for apprehending the mechanistic paradigms of PDAC with normal KRAS, for which no effective therapy is available.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716579PMC
http://dx.doi.org/10.1016/j.celrep.2022.111623DOI Listing

Publication Analysis

Top Keywords

pancreatic ductal
8
ductal adenocarcinoma
8
genetic alterations
8
nf1
7
pdac
7
nf1 loss
4
loss function
4
function alternative
4
alternative initiating
4
initiating event
4

Similar Publications

3-O-sulfation of heparan sulfate (HS) is the key determinant for binding and activation of Antithrombin III (AT). This interaction is the basis of heparin treatment to prevent thrombotic events and excess coagulation. Antithrombin-binding HS (HSAT) is expressed in human tissues, but is thought to be expressed in the subendothelial space, mast cells, and follicular fluid.

View Article and Find Full Text PDF

Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma.

Adv Sci (Weinh)

September 2025

State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.

Perineural invasion (PNI) is a common pathological characteristic of pancreatic ductal adenocarcinoma (PDAC), closely linked to postoperative recurrence, metastasis, and unfavorable prognosis. Nevertheless, the precise mechanisms that govern PNI in PDAC remain poorly elucidated. Here, group-specific component protein (GC) is identified as one of the most significantly upregulated genes related to PNI, primarily derived from malignant ductal cells compared to other cell types.

View Article and Find Full Text PDF

This case report presents a complex case of acute cholecystitis, cholangitis, pancreatitis, intrahepatic abscesses, and sepsis without biliary obstruction, highlighting the challenges of managing multi-organ involvement in a critically ill individual. The patient, a middle-aged male, presented with fever, jaundice, and abdominal pain, with imaging revealing biliary ductal dilation, a distended gallbladder, and a staghorn calculus. Laboratory findings showed elevated liver enzymes, bilirubin, and lipase, supporting the diagnosis of acute cholecystitis, cholangitis, and pancreatitis.

View Article and Find Full Text PDF

The clinical use of gemcitabine (GEM), a frontline chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC), is limited by its short half-life, rapid systemic clearance, associated dose-limiting toxicities and a faster development of resistance in pancreatic cancer. Aspirin (ASP), a repurposed NSAID, has been shown to sensitize PDAC cells to GEM through modulation of multiple oncogenic and inflammatory pathways. However, its clinical use is restricted by dose-dependent gastrointestinal toxicity.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDA) is defined by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., PD-1 and CTLA-4).

View Article and Find Full Text PDF